Heart - Cardiology & Cardiovascular Surgery


Mount Sinai’s Cardio-Oncology program provides a platform of close collaboration between cardiologists specializing in the cardiac effects of chemotherapy with medical oncologists, radiation oncologists and oncology surgeons, allowing us to customize the best cancer therapies for our patients balanced against their cardiac effects.

"This includes specialized risk stratification, surveillance with sophisticated echocardiographic and other imaging techniques, preventative therapy, early diagnosis and treatment of heart disease in case it develops or has pre-existed in patients undergoing cancer chemotherapy or radiation,” says Gagan Sahni, MD, FACC, FACP, Director of the Cardio-Oncology Clinic and Cardiology Consult Services at The Mount Sinai Hospital.

There are approximately 15.5 million adult cancer survivors in the United States today, owing largely to advances made in the field of oncology.  More than 40% of these cancer survivors above the age of 50 will develop cardiovascular disease. This occurs due to increasing age of the patients, common risk factors of both cancer and heart disease, and damage to the heart from certain cancer treatments, notably chemotherapy and radiation.

The Cardio-Oncology clinic at Mount Sinai Heart was established by Dr. Sahni in 2013. The clinic treats a large volume of cancer patients with a focus on providing the best possible cancer survival rates, while minimizing the damaging effects of chemotherapy, radiation, and other cancer therapeutics on the heart.

We provide our cancer patients efficient and timely access to cardiology services, including cardiac risk assessment, interventions for minimizing risk, assessment of the cardiac effects of cardiotoxic chemotherapies, use of the latest imaging techniques to detect early cardiotoxicity, and early diagnosis and treatment of heart disease. We achieve all of this through open dialogue between patients, their families, and our multi-disciplinary team of cardio-oncologists, medical oncologists, hematologists, and radiation oncologists. This approach lays the foundation for better clinical outcomes, enhanced research in the rapidly evolving field of cardio-oncology, and personalized cardiac services under one roof, in an accessible and compassionate environment.

“We have recognized together that emerging chemotherapeutics in oncology, although very effective, have an undeniable cardiac risk. By tackling both so-called ‘evils’ in a collaborative way, we thereby ensure the best results for our patients,” says Dr. Sahni.

Our Services

To prevent and manage cardiovascular risks of oncology treatment, we offer the following personalized services:

  • Risk assessment of cardiotoxicity caused by chemotherapy and/or radiation
  • Careful management of patients with pre-existing heart disease on complex cardiotoxic chemotherapy in both inpatient and outpatient settings
  • Prompt and ongoing collaboration among our cardio-oncologists and your hematologist, oncologist or radiation oncologists 
  • Access to latest cardiac imaging techniques including strain imaging and 3D echocardiography, cardiac magnetic resonance imaging, and monitoring of cardiac biomarkers to detect and monitor early cardiotoxicity
  • Early prevention and treatment of cardiac disease including congestive heart failure, cardiac amyloidosis, coronary artery disease, arrhythmias, and pericardial disease that may result from cancer therapeutics

Mount Sinai Cardio-Oncology in the News and Academia

Our clinic has received widespread recognition for its clinical and research achievements. We have been featured in Time magazineCardiology Today, and Healio HemOnc Today.

In addition, we have presented research abstracts at major international meetings including the American College of Cardiology, the American Heart Association, and the American Society of Hematology.  Besides developing the Cardio-Oncology Program at Mount Sinai Heart, Dr. Sahni spreads the message of Cancer and Heart disease more broadly through radio talk shows educating people about the heart effects of cancer therapies. She has co-authored a chapter on Cardiovascular Disease in Cancer Patients in the 14th Edition of Hurst’s The Heart and has lectured extensively on the topic at several institutions in the tri-state area.